Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group
Online Formulary

13.3.1.4 High-cost Drugs (Immunosuppressants)

Click Here for Kent and Medway Health Economy National Tariff Excluded Drugs Manual -High Cost Drugs

Baricitinib This High Cost Drug has been approved for the following indications: -Moderate to severe atopic dermatitis as per NICE Guidance 
For more information and NICE Guidance
Click Here
 Baricitinib for treating moderate to severe atopic dermatitis NICE Guidance TA681
ICB commissioned - approval via Blueteq
Abrocitinib    Tralokinumab  Upadacitinib These High Cost Drugs have been approved for the following indications: - Moderate to severe atopic dermatitis as per NICE Guidance 
For more information and NICE Guidance 
Click Here		 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis NICE Guidance TA814
ICB commissioned - approval via Blueteq (Adults) NHSE commissioned - (Paediatrics )
  Deucravaticinib This High Cost Drug has been approved for the following indications: - treatment of moderate to severe plaque psoriasis as per NICE Guidance 
For more information and NICE Guidance 
Click Here		 Deucravacitinib for treating moderate to severe plaque psoriasis NICE Guidance TA907
ICB commissioned - approval via Blueteq
  Infliximab biosimilar biosimilar - Flixabi® This High Cost Drug has been approved for the following indications: - treatment option for adults with plaque psoriasis as per NICE Guidance 
For more information and NICE Guidance 
Click Here		 Infliximab for the treatment of adults with psoriasis NICE Guidance TA134
ICB commissioned - approval via Blueteq
  Lebrikizumab Ebglyss® This High Cost Drug has been approved for the following indications: - for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in Adults (18+ years ICB commissioned) Adolescents (12 - 17 years NHSE commissioned) as per NICE Guidance 
For more information and NICE Guidance 
Click Here		 Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over NICE Guidance TA986
ICB/NHSE commissioned - approval via Blueteq
  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •